Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,421.89
    -1,001.11 (-1.95%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Germany's Stada is "very selective" on acquisitions, CEO says

Reuters - UK Focus

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright and will for now focus mainly on striking production and development deals with partners, its chief executive told Reuters.

"We are very selective but we take a look at everything," said CEO Peter Goldschmidt, who took the helm a year ago, adding that Stada had strong organic growth and would prioritise partnerships.

The private equity-backed company on Wednesday reported an increase in adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of 13% to 295 million euros ($310.61 million) during the fist half-year.

Sales gained 11% to 1.26 billion euros in the same period. ($1 = 0.8950 euros) (Reporting by Ludwig Burger and Patricia Weiss, Editing by Tassilo Hummel)